# US 2001/0027250 A1 · Activator protein of human acid maltase and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0027250 A1
- Document ID: US20010027250A1
- Status: Published application
- Kind: A1
- Application number: 09/728,997
- Filed: 2000-12-01
- Published: 2001-10-04
- Earliest claimed: 1997-05-26
- Inventors: Frank T. Martiniuk
- Web page: https://patentgrep.com/patent/US20010027250A1

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- C07K 16/18: against material from animals or humans
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to compositions and methods for treating glycogen storage disease, such as GSD II. A human activator enzyme, termed ASA, of acid a a-glycosidase, (GAA) or acid maltase, a lysosomal enzyme, is specifically defined and characterized. The AGA has been found to increase the activity of human acid α glycosidase activity to at least 10-fold, relative to the activity of GAA in the absence of the activator protein. The invention thus also provides for a method of increasing the activity of GAA, particularly through the action of AGA. The AGA has an approximate molecular weight of 25-30 kD, and is found to be heat stable. In addition, the AGA is found to have an extended shelf life without significant loss of ability to activate GAA. The invention further reports other enzymes such as β-Fucosidase, β-Lactase, and β-Galactosidase, that provide enhancement of enzymatic activity nine-fold, six-fold, and five-fold, for breakdown of their respective substrate protein. These enzymes are non-lysosomal enzymes. These are anticipated to be useful in treatment of disease related to reduced enzymatic activity levels in an animal.

## Claims

### Claim 1

A composition comprising a human activation protein of human acid maltase (AGA), said activation protein being capable of enhancing human placental acid alpha glucosidase (GAA) activity at least 10-fold over GAA activity in the absence of human acid maltase (AGA).

### Claim 2 (depends on 1)

The composition of claim 1 when the activator protein is further defined as having a molecular weight of about 25 kD to about 30 kD as determined on a Sephadex G75 column.

### Claim 3 (depends on 1)

The composition of claim 1 farther defined as heat stable.

### Claim 4 (depends on 1)

A monoclonal antibody having specific binding affinity for a human activation protein of human acid maltase, produced by a process of:
injecting a mammal capable of mounting an immune response upon exposure to an antigen with an immune-response evoking amount of heat inactivated human urine or a composition of claim 1;
repeating the injection four times, two weeks apart;
monitoring sequential blood samples from the injected animal to determine a titer of polyclonal AGA antibody levels in the animal;
collecting the spleen from each treated animal;
preparing a hybridoma cell line from said spleen and an immortalized cell line;
culturing said hybridoma cell line for a period of time suitable for production of monoclonal antibody from said hybridoma cell line; and
collecting monoclonal antibody having specific binding affinity for human activation protein of human acid maltase.

### Claim 5 (depends on 4)

The monoclonal antibody of claim 4 wherein the animal is injected with heat inactivated urine comprising a human activator protein (AGA) of human acid maltase.

### Claim 6 (depends on 1)

A method for increasing acid alpha glucosidase activity in a patient having acid maltase deficiency comprising administering an effective amount of the human GAA activator protein, AGA of claim 1.

### Claim 7 (depends on 6)

The method of claim 6 wherein the acid maltase deficiency is further defined as GSD II.

### Claim 8 (depends on 1)

The composition of claim 1 wherein said activator protein is further defined as having a molecular weight of about 25-30 kD.

### Claim 9

A composition comprising β-Fucosidase, said β-Fucosidase being capable of enhancing biological activity up to nine-fold.

### Claim 10

A composition comprising β-Lactase, said β-Lactase being capable of enhancing biological activity of up to six-fold.

### Claim 11

A composition comprising β-Galactosidase, said β-Galactosidase being capable of enhancing biological activity up to five-fold.
